( NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it will present new treatment comparison results evaluating ANKTIVA ® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Jimi Stewart, a rollerblading enthusiast from Austin, Texas, was diagnosed with a type of non-muscle invasive bladder cancer ...

As new therapies emerge, particularly for non-muscle invasive disease, clinicians and patients are faced with increasingly ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...

ImmunityBio will present new findings on its Anktiva immunotherapy combined with BCG for non-muscle-invasive bladder cancer ...

Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis. Survival is comparably poor for patients who develop metastases directly after non-muscle invasive ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

But when Jimi began experiencing bladder cancer symptoms, including blood in his urine, he felt a different kind of rush. It ...